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Background: An open-label, single-arm prospective study was
conducted to evaluate the efficacy and toxicity of the combination of
gemcitabine and tegafur-uracil (UFT) in patients with advanced
nonsmall-cell lung cancer (NSCLC) after the failure of previous
platinum-containing regimens.
Patients and Methods: Patients with advanced NSCLC received
200 mg/m2 of UFT twice daily from day 1 through 14 plus 900
mg/m2 of gemcitabine per day via intravenous injection on days 8
and 15. This regimen was repeated every 3 or 4 weeks.
Results: A total of 40 patients were enrolled. Eleven patients (28%;
95% confidence interval [CI], 15–44%) achieved a partial response.
The median progression-free survival, median overall survival, and
1-year survival rate were 4.0 months (95% CI, 3.3–6.7 months),
12.6 months (95% CI, 7.0–22.3 months), and 51% (95% CI,
33–66%), respectively. The most common grade 3 or 4 toxicity was
neutropenia (38%; 95% CI, 23–54%) and the rate of grade 3 or 4
nonhematologic toxicity remained at less than 5%. A multivariate
Cox model showed that adenocarcinoma, nonsmoking history, and
good performance status predicted better survival.
Conclusions: Combination chemotherapy with UFT and gemcitab-
ine showed a promising effectiveness and acceptable toxicity for
patients with platinum-resistant NSCLC.
Key Words: Adenocarcinoma, Advanced nonsmall-cell lung cancer,
Gemcitabine, Nonsmoking, Second-line chemotherapy, Tegafur-uracil.
(J Thorac Oncol. 2008;3: 637–642)
Systemic chemotherapy plays an important role in thetreatment of non-small cell lung cancer (NSCLC), and in
the past decade combination chemotherapy regimens includ-
ing platinum have become the standard first-line treatments
for advanced NSCLC.1–7 Several meta-analyses, however,
have found that these regimens confer only a limited survival
benefit.8 If a first-line therapy fails, single agents, including
docetaxel,9,10 pemetrexed,11 and erlotinib,12 can be adminis-
tered. A response rate of more than 20% is sufficient to justify
consideration of a regimen for second-line use, especially in
patients with good performance status.
Gemcitabine is one of the most active new drugs
against NSCLC. It has antitumor activity comparable to that
of cisplatin with etoposide but produces less toxicity.13–15 In
vitro, gemcitabine shows significant activity against plati-
num-resistant cell lines16 and the reported response rates of
gemcitabine monotherapy in the second-line treatment is 6 to
21% with median survival time ranging from 4 to 7.9
months.17–20 Tegafur-uracil (UFT) is an oral agent composed
of a 1:4 molar ratio of tegafur, a prodrug that is converted to
5-fluorouracil (5-FU), and uracil, which elevates serum levels
of 5-FU by inhibiting its enzymatic degradation. Although no
data of single agent UFT is available in patients with ad-
vanced NSCLC, a recent randomized study in 984 patients
with stage I adenocarcinoma has confirmed that postoperative
adjuvant therapy with UFT increases overall survival.21 Both
gemcitabine and 5-FU are antimetabolites, but they inhibit
DNA synthesis via different pathways. Gemcitabine most
likely exerts its cytotoxic effects through phosphorylation by
deoxycytidine kinase into gemcitabine triphosphate, which is
then incorporated into DNA; in contrast, 5-FU inhibits DNA
synthesis through the binding of its derivative, fluorodeoxy
monophosphate, to thymidylate synthase. These different
antitumor mechanisms suggest a potential synergism between
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gemcitabine and 5-FU, which has been observed in vitro
studies of various cancer cell lines.22
Our previous phase I study in 24 patients with advanced
NSCLC reported that the combination of UFT and gemcit-
abine is both well-tolerated and effective. The most frequent
toxicities of this regimen were hematologic. The objective
response rates were 45% (5 of 11 patients) in chemonaı¨ve
patients and 23% (3 of 13 patients) in patients previously
treated with a platinum-containing regimen. The most appro-
priate schedule and dosing were determined to be 200 mg/m2
twice daily on days 1 through 14 with 900 mg/m2 of gem-
citabine on days 8 and 15.23 This study was then followed by
a phase II study in 44 chemonaı¨ve patients with advanced
NSCLC in which the above schedule of UFT and gemcitabine
achieved a very high response rate of 41% (95% confidence
interval [CI], 26–55%).24 In the present study, we examined
the efficacy and safety of this combination as second-line
chemotherapy in patients with platinum-resistant NSCLC.
PATIENTS AND METHODS
Patient Eligibility
Patients were eligible for enrollment if they had histo-
logically or cytologically confirmed stage IIIB or IV NSCLC;
with measurable lesions; previously treated with one or more
regimens, at least one of which is platinum-based regimens;
an Eastern Cooperative Oncology Group performance status
of zero to two; and a life expectancy of at least 3 months. The
eligibility criteria regarding organ function were as follows: a
leukocyte count of 4000 to 12,000/mm3; a platelet count of
100,000/mm3 or greater; a hemoglobin level of 9.0 g/dL or
greater; a serum bilirubin level less than 1.5 mg/dL; serum
levels of aspartate aminotransferase and alanine aminotrans-
ferase of twice the upper limit or less; a serum creatinine level
of 1.5 mg/dL or less. For pretreatment tumor-staging, all
patients underwent computed tomography of the thorax and
upper abdomen. Metastatic brain tumors were evaluated by
either magnetic resonance imaging or enhanced computed
tomography, whereas metastases to bone were evaluated by
either radioisotopic bone scan or FDG-PET. All imaging tests
were required to be conducted within 4 weeks before patient
registration. Any patients who had severe complications,
concomitant other malignancies, pleural effusion necessitat-
ing treatment, or symptomatic cerebral involvement were
excluded from the study. Patients were enrolled at least 4
weeks after their most recent previous treatment. Written
informed consent was required before enrollment.
Treatment Schedule
The present study used the same schedule in a previous
phase II study for chemonaı¨ve patients.24 Patients received
UFT (200 mg/m2) twice daily orally before meals on days 1
through 21 plus gemcitabine (900 mg/m2 on days 8 and 15)
by intravenous infusion over 30 minutes. On the day the
gemcitabine was to be administered, a complete blood count
was obtained; gemcitabine was administered only if the
leukocyte count was at least 2000/mm3 and the platelet count
was at least 70,000/mm3. If these requirements were not met,
administration of gemcitabine was postponed for a maximum
of 4 days. The treatment regimen was repeated every 3 or 4
weeks and at least two cycles were scheduled to be admin-
istered unless disease progression or an unacceptable toxicity
occurred. The next cycle was started only if the leukocyte
count was at least 3000/mm3 and if the other eligibility
criteria regarding organ function were satisfied. The dose of
gemcitabine was reduced to 800 mg/m2 either if grade 4
hematotoxicities or grade 3 nonhematotoxicities occurred or
if the administration of gemcitabine on day 15 was skipped in
a previous cycle.
Evaluation of Response and Toxicity
Objective tumor responses were based on findings of
computed tomography and were evaluated with World Health
Organization criteria. The response status of all patients
considered to be showing a complete response or partial
response (PR) was confirmed the extramural review meeting.
Any adverse events were graded according to the National
Cancer Institute-Common Toxicity Criteria, version 2.0.
Statistical Analysis
This study was designed as a multicenter study among
three participating institutions. The primary end point was the
objective response rate, defined as the percentage of patients
with a best response of complete response or PR among all
eligible patients, and its 95% CI was based on the exact
binomial distribution. The sample size was determined as
follows. Assuming that a response rate of 25% in eligible
patients would indicate potential usefulness of the combina-
tion of UFT and gemcitabine, whereas a rate of 10% would
be the lower limit of interest, and   0.05 (one-side) and
 0.20, the estimated required number of patients was 38.25
In light of the possibility of patients becoming ineligible or
providing no data for evaluation, we decided the sample size
would be 40 registered patients. No interim analysis was
planned. Secondary endpoints were toxicity, progression-free
survival, and overall survival. The duration of progression-free
survival or overall survival was measured from the date of
registration to the date of event occurrence or last follow-up.
Survival distribution was estimated with the method of
Kaplan-Meier and confidence intervals were based on the
Greenwood’s formula. Pairs of survival curves were com-
pared by the log-rank test.
An exploratory multivariate Cox model was applied to
examine possible associations between baseline factors and
overall survival. After screening out candidate factors by the
log-rank test, a multivariate Cox model with a backward step-
wise approach was performed to determine the final model that
identifies independent prognostic factors. The proportional haz-
ard assumption for each covariate was evaluated by the log-
cumulative hazard plot and the Schoenfeld residuals.26
All p-values reported are two-tailed, and statistical analy-
ses were performed with the SAS for Windows, version 9.1.
RESULTS
The initial planned accrual period was 3 years. How-
ever, several studies in patients with previously treated
NSCLC had been conducted concurrently with our study
and the number of such studies was indeed more than
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anticipated at the commencement of this study, resulting in
a very slow accrual. Therefore, enrollment was extended
and the planned cohort of 40 patients was registered from
July 2000 through December 2005. All the patients met the
eligibility criteria and received the study treatment. Thus,
treatment delivery, efficacy and toxicity were evaluated in
the 40 patients.
Patient Characteristics
Patient characteristics are summarized in Table 1. Me-
dian age was 65 years (range, 45–80). Of the 40 patients, 26
(65%) were male, 15 (38%) had a performance status of 2, 30
(75%) had metastatic disease, and 30 (75%) had adenocarci-
noma. Thirty-three (83%) had received cisplatin-containing
regimens, 26 (65%) had received docetaxel or paclitaxel or
both, 16 (40%) had received topoisomerase I or II inhibitors
(irinotecan or amrubicin) and 8 (20%) had received epidermal
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
A total of 27 (68%) patients had received two or more
regimens previously.
Treatment Delivery
A total of 164 treatment cycles were administered to the
40 patients. The median number of administered cycles was
3 (range, 1–10). Thirty-seven (93%) patients completed 2
cycles of the protocol treatment, whereas 3 patients discon-
tinued treatment before completing 2 cycles because of pro-
gression of tumor (1 patient), patient refusal (1 patient), or
allergic reaction (1 patient). The administration of gemcitab-
ine on day 15 was skipped in 10 (6%) of the 164 cycles.
Doses were decreased to 800 mg/m2 in 6 patients (15%).
Toxicity
The main toxicities were hematologic (Table 2). Grade
3 or 4 neutropenia was observed in 38% of the patients and
grade 4 in 20%. Grade 4 anemia was observed in 1 patient,
but grade 4 thrombocytopenia did not occur. For nonhema-
totoxicity, there were 4 cases with grade 3 (2 for anorexia, 1
for diarrhea, and 1 for pneumonitis) whereas no patient
experienced grade 4 events.
Tumor Response
Of the 40 patients, 11 showed a PR, resulting in an
objective response rate of 28% (95% CI, 15–44%). Twenty-
two patients (55%) showed no change, 5 (13%) had progres-
sive disease, and 2 were not evaluable.
Progression-Free and Overall Survival
Median progression-free survival and overall survival
were 4.0 months (95% CI, 3.3–6.7 months) and 12.6 months
(7.0–22.3 months), respectively (Fig. 1). Thirty of the 40
patients were confirmed to have died. The remaining 10
patients were lost to follow-up, with a median follow-up time
of 9.0 months (range, 1.8–55.9 months). The overall survival
rates at 6, 12, and 24 months were 66% (95% CI, 48–78%),
51% (33–66%), and 23% (10–39%), respectively.
To investigate the association between the baseline
characteristics and overall survival, a planned exploratory
analysis was performed. Table 3 shows the result of univar-
iate analysis with the log-rank test for each variable. Char-
acteristics significantly correlated with overall survival were
the following five features: sex, performance status, tumor
histologic type, smoking history, and response to previous
chemotherapy (Fig. 2). To identify independent prognostic
factors that were associated with survival, the Cox regression
with backward elimination technique at 5% significance level
was employed among these five significant factors. This
resulted in three factors being retained in the final model:
performance status, tumor histologic type and smoking his-
tory (Table 4). Namely, good performance status, adenocar-
cinoma, and nonsmoking history could independently pre-
dicted better survival outcome. Although adenocarcinoma
TABLE 2. Hematologic and Nonhematologic Toxicities in
40 Patients
Toxicity
Grade
Total (%)3 4
Leukopenia 12 2 14 (35)
Neutropenia 7 8 15 (38)
Anemia 9 1 10 (25)
Thrombocytopenia 9 0 9 (23)
AST/ALT increaseda 2 0 2 (5)
Anorexia 2 0 2 (5)
Diarrhea 1 0 1 (3)
Pneumonitis 1 0 1 (3)
a ALT/AST, alanine aminotransferase/aspartate aminotransferase.
TABLE 1. Patients Characteristics
Characteristics No. of Patients
Median age (range), yr 65 (45–80)
Sex
Male/female 26/14
Performance status
0/1/2 12/13/15
Stage
IIIB/IV 10/30
Tumor histologic type
Adenocarcinoma/others 30/10
Smoking history
No/yes 15/25
No. of previous chemotherapy regimens
1/2/3 13/22/5
Response to previous chemotherapy
Sensitive/resistant 17/23
Previously administered drugs
Cisplatin/carboplatin/both 25/7/8
Paclitaxel/docetaxel/both 8/15/3
Vinorelbine 13
Irinotecan/amrubicin 11/5
Pemetrexed 2
EGFR-TKI 8
Previous surgery 7
Previous thoracic irradiation 16
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and nonsmoking history may be predictive factors of EGFR-
TKI efficacy according to recent studies and indeed several
patients received it after failure of UFT/gemcitabine, the
same result holds in light of the possible effect of post
EGFR-TKI use (Table 5).
DISCUSSION
To date, three phase III trials to develop second-line
chemotherapies have been performed in patients with ad-
vanced NSCLC.8–10 Because of the results of these studies,
docetaxel or pemetrexed are now considered the most effec-
tive single agents for chemotherapy after the failure of the
first-line platinum-based regimens. On the hand, several sin-
gle-arm phase II studies have found that combination regi-
mens have possible benefits on survival outcome in the
FIGURE 1. Kaplan-Meier curves for
progression-free survival and overall
survival.
FIGURE 2. Kaplan-Meier curves for
overall survival according to four
factors including sex, performance
status, tumor histologic type, and
smoking history.
TABLE 3. Association of Baseline Characteristics with
Overall Survival (Univariate Analysis Log-Rank test)
p
Age (65 vs 65) 0.4630
Sex (female vs male) 0.0339*
Performance status (2 vs 0/1) 0.0001*
Stage (IV vs IIIB) 0.8791
Histologic type (adenocarcinoma vs others) 0.0001*
Smoking history (no vs yes) 0.0001*
Number of previous chemotherapy (1 vs 2/3) 0.6767
Response to previous chemotherapy (sensitive vs
refractory)
0.0348*
*Statistically significant at 5% level.
TABLE 4. Association of Baseline Characteristics with
Overall Survival (Multivariate Cox Analysis after the
Backward Stepwise Selection)
HR
95% CI
of HR p
Performance status (2 vs 0/1) 3.823 (1.53–9.53) 0.0040
Histologic type (adenocarcinoma vs others) 0.104 (0.03–0.36) 0.0004
Smoking history (no vs yes) 0.371 (0.16–0.87) 0.0257
HR, hazard ratio; CI, confidence interval.
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second-line treatment of advanced NSCLC. Although four ran-
domized trials (one phase III and three phase II studies) of
second-line therapy have compared some of such the experi-
mental combination regimens with a standard single agent,27–30
all failed to demonstrate a survival benefit over single agents.
One important reason for the negative results was frequent
severe toxicities in the combination regimens, which easily led
to poor compliance of the treatment. Therefore, the development
of combinations with lesser toxicity would be a necessary
improvement over standard single-agent therapies for previously
treated patients with NSCLC. In this regard, particularly notable
was that the incidence of adverse effects of our protocol regimen
was much lower than that of other second-line combination
treatments. The antitumor activity shown by UFT and gemcit-
abine was satisfactory with a high response rate of 28%. Fur-
thermore, its efficacy is quite comparable to that of other com-
binations examined in previous studies. Thus, given its favorable
toxicity, the combination of UFT and gemcitabine warrants
further phase III evaluation with the standard control arm of
docetaxel or pemetrexed monotherapy.
We obtained an impressive result when compared with
the recent Taiwanese study on the same combination with the
reported response rate of 15.6%.31 The difference may be
because their daily dose of UFT was half of ours. In addition,
gemcitabine was infused on days 1 and 8 in their regimen
whereas on days 8 and 15 in ours. The preclinical data
indicated that prior 5-FU followed by gemcitabine can yield
higher response rate than gemcitabine followed by 5-FU.22
An exploratory analysis by multivariate Cox model
showed that good performance status, adenocarcinoma and
nonsmoking history can predict increased survival. Although
these factors are recognized as key factors for a good re-
sponse and survival prolongation with EGFR-TKI32,33 and
several patients in our study were treated with EGFR-TKI
after the failure of UFT and gemcitabine, our analysis con-
cluded that the survival benefits associated with adenocarci-
noma and nonsmoking history are not biased by EGFR-TKI
use. It is unclear whether these are prognostic factors for
survival or predictive factors for efficacy of UFT/gemcitab-
ine, but at least it is of value to recognize that these factors
may have possible prognostic effect regardless of the EGFR-
TKIs; the percentages of patients with adenocarcinoma and
nonsmoking history should be carefully considered when
interpreting the results of clinical trials.
In conclusion, following the earlier trial of UFT and
gemcitabine in chemonaı¨ve patients, the present study has
demonstrated that the same combination is also promising as
a second-line treatment in patients with NSCLC previously
treated with platinum-containing regimens. Good perfor-
mance status, adenocarcinoma, and nonsmoking history are
associated with longer survival. Further study of this second-
line chemotherapy in advanced NSCLC is highly warranted.
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